CS200166B2 - Method of producing n-substituted prostaglandincarboxamides - Google Patents

Method of producing n-substituted prostaglandincarboxamides Download PDF

Info

Publication number: CS200166B2
Authority: CS; Czechoslovakia
Prior art keywords: trans; cis; substituted; carboxamide; multiplet
Prior art date: 1972-06-07

Application number

CS734136A

Other languages

Czech (cs)

English (en)

Inventor

Thomas K Schaaf

Leonard J Czuba

Hans-Juergen Hess

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1972-06-07

Filing date

1973-06-07

Publication date

1980-08-29

1973-06-07 Application filed by Pfizer filed Critical Pfizer

1977-07-25 Priority to CS774937A priority Critical patent/CS200168B2/cs

1977-07-25 Priority to CS774936A priority patent/CS200167B2/cs

1980-08-29 Publication of CS200166B2 publication Critical patent/CS200166B2/cs

Links

238000000034 method Methods 0.000 title claims description 7
-1 C 3-8 cycloalkanoyl Chemical group 0.000 claims abstract description 31
150000001875 compounds Chemical class 0.000 claims abstract description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
125000003435 aroyl group Chemical group 0.000 claims abstract description 7
125000001589 carboacyl group Chemical group 0.000 claims abstract description 5
125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 4
229910052736 halogen Chemical group 0.000 claims abstract description 4
150000002367 halogens Chemical group 0.000 claims abstract description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 63
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
USCSRZNYDWXTMH-UHFFFAOYSA-N 2-(oxan-2-yloxyperoxy)oxane Chemical compound O1CCCCC1OOOC1OCCCC1 USCSRZNYDWXTMH-UHFFFAOYSA-N 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
229910052802 copper Inorganic materials 0.000 claims description 2
125000004185 ester group Chemical group 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
125000004043 oxo group Chemical group O=* 0.000 claims description 2
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 claims description 2
125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
125000004391 aryl sulfonyl group Chemical group 0.000 abstract description 3
150000004714 phosphonium salts Chemical class 0.000 abstract 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 abstract 2
OQQQSCLHEDSFOH-UHFFFAOYSA-N 5-bromopentanamide Chemical compound NC(=O)CCCCBr OQQQSCLHEDSFOH-UHFFFAOYSA-N 0.000 abstract 1
OKRUMSWHDWKGHA-UHFFFAOYSA-N 5-bromopentanoyl chloride Chemical compound ClC(=O)CCCCBr OKRUMSWHDWKGHA-UHFFFAOYSA-N 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
239000000203 mixture Substances 0.000 description 29
229910052757 nitrogen Inorganic materials 0.000 description 29
239000000243 solution Substances 0.000 description 28
150000003180 prostaglandins Chemical class 0.000 description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
150000003857 carboxamides Chemical class 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
229940094443 oxytocics prostaglandins Drugs 0.000 description 18
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 17
239000012535 impurity Substances 0.000 description 15
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 13
229960002986 dinoprostone Drugs 0.000 description 13
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 13
239000003921 oil Substances 0.000 description 12
235000019198 oils Nutrition 0.000 description 12
230000009102 absorption Effects 0.000 description 11
238000010521 absorption reaction Methods 0.000 description 11
230000000694 effects Effects 0.000 description 11
238000010898 silica gel chromatography Methods 0.000 description 10
238000004440 column chromatography Methods 0.000 description 9
239000003480 eluent Substances 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
238000005303 weighing Methods 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
150000001408 amides Chemical class 0.000 description 8
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
230000004044 response Effects 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
241000700199 Cavia porcellus Species 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
239000012230 colorless oil Substances 0.000 description 6
239000010779 crude oil Substances 0.000 description 6
QKDCLUARMDUUKN-XMMPIXPASA-N 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide Chemical compound N1=C(O[C@H]2CN(CC2)C(=O)C=C)C(CC)=NC(C(N)=O)=C1NC(C=C1)=CC=C1N(CC1)CCC1N1CCN(C)CC1 QKDCLUARMDUUKN-XMMPIXPASA-N 0.000 description 5
206010000210 abortion Diseases 0.000 description 5
231100000176 abortion Toxicity 0.000 description 5
230000001766 physiological effect Effects 0.000 description 5
210000002460 smooth muscle Anatomy 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
238000011282 treatment Methods 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
238000010828 elution Methods 0.000 description 4
229960001340 histamine Drugs 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
GGNHZXRCRZASKP-JTPNTKCXSA-N (z)-n-acetyl-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enamide Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)NC(C)=O GGNHZXRCRZASKP-JTPNTKCXSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
208000009079 Bronchial Spasm Diseases 0.000 description 3
208000014181 Bronchial disease Diseases 0.000 description 3
206010006482 Bronchospasm Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical class OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
240000005578 Rivina humilis Species 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
229940124630 bronchodilator Drugs 0.000 description 3
239000006260 foam Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000008101 lactose Chemical class 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000003033 spasmogenic effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000002254 contraceptive effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
230000035558 fertility Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000002329 infrared spectrum Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
238000002390 rotary evaporation Methods 0.000 description 2
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
241000700198 Cavia Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
101100468705 Danio rerio rhoac gene Proteins 0.000 description 1
102100029095 Exportin-1 Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
101000770943 Homo sapiens Exportin-1 Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020802 Hypertensive crisis Diseases 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
239000010949 copper Substances 0.000 description 1
238000003795 desorption Methods 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
FONOSWYYBCBQGN-UHFFFAOYSA-N ethylene dione Chemical compound O=C=C=O FONOSWYYBCBQGN-UHFFFAOYSA-N 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000004460 liquid liquid chromatography Methods 0.000 description 1
230000003529 luteolytic effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
LWRYDHOHXNQTSK-UHFFFAOYSA-N thiophene oxide Chemical group O=S1C=CC=C1 LWRYDHOHXNQTSK-UHFFFAOYSA-N 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
230000035884 vasodepression Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5407—Acyclic saturated phosphonium compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Furan Compounds (AREA)
Pyrane Compounds (AREA)

CS734136A 1972-06-07 1973-06-07 Method of producing n-substituted prostaglandincarboxamides CS200166B2 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
CS774937A CS200168B2 (cs)	1972-06-07	1977-07-25	Způsob výroby substituovaného karboxamidtrifenylfosfoniumbromidu
CS774936A CS200167B2 (cs)	1972-06-07	1977-07-25	Způsob výroby ll,15-bis(tetrahydropyranyl)etheru prostaglandinkarboxamidu

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US26051872A	1972-06-07	1972-06-07

Publications (1)

Publication Number	Publication Date
CS200166B2 true CS200166B2 (en)	1980-08-29

Family

ID=22989486

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS734136A CS200166B2 (en)	1972-06-07	1973-06-07	Method of producing n-substituted prostaglandincarboxamides

Country Status (24)

Country	Link
JP (2)	JPS5715591B2 (xx)
AR (1)	AR207434A1 (xx)
AT (1)	AT340069B (xx)
BE (1)	BE800580A (xx)
CA (1)	CA985280A (xx)
CH (3)	CH591511A5 (xx)
CS (1)	CS200166B2 (xx)
DD (2)	DD109211A5 (xx)
DE (1)	DE2329092A1 (xx)
ES (3)	ES415611A1 (xx)
FI (1)	FI58327C (xx)
FR (2)	FR2187344B1 (xx)
GB (2)	GB1439512A (xx)
HU (3)	HU170491B (xx)
IE (1)	IE38058B1 (xx)
IL (2)	IL42385A (xx)
IN (1)	IN138966B (xx)
LU (1)	LU67754A1 (xx)
NL (2)	NL160814C (xx)
NO (2)	NO146538C (xx)
PH (2)	PH14204A (xx)
SE (3)	SE415883B (xx)
YU (1)	YU36498B (xx)
ZA (1)	ZA733763B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX3291E (es) *	1975-04-23	1980-08-22	Upjohn Co	Procedimiento para preparar analogos de prostaglandinas
US6395787B1 (en)	2000-02-08	2002-05-28	Allergan Sales, Inc.	Ocular hypotensive lipids
US6476064B1 (en) *	2001-06-13	2002-11-05	Allergan, Inc.	Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3187043A (en) *	1962-05-18	1965-06-01	Monsanto Co	Monohalophosphonium halides

1973
- 1973-01-01 AR AR248467A patent/AR207434A1/es active
- 1973-05-28 SE SE7307522A patent/SE415883B/xx unknown
- 1973-05-29 GB GB4209675A patent/GB1439512A/en not_active Expired
- 1973-05-29 CA CA172,672A patent/CA985280A/en not_active Expired
- 1973-05-29 GB GB2561373A patent/GB1439511A/en not_active Expired
- 1973-05-29 IL IL42385A patent/IL42385A/xx unknown
- 1973-05-30 FI FI1762/73A patent/FI58327C/fi active
- 1973-05-31 IN IN1278/CAL/73A patent/IN138966B/en unknown
- 1973-06-04 PH PH14689A patent/PH14204A/en unknown
- 1973-06-04 ZA ZA733763A patent/ZA733763B/xx unknown
- 1973-06-05 IE IE896/73A patent/IE38058B1/xx unknown
- 1973-06-06 HU HUPI476A patent/HU170491B/hu unknown
- 1973-06-06 HU HUPI384A patent/HU170487B/hu unknown
- 1973-06-06 NO NO2379/73A patent/NO146538C/no unknown
- 1973-06-06 HU HUPI477A patent/HU170200B/hu unknown
- 1973-06-06 ES ES415611A patent/ES415611A1/es not_active Expired
- 1973-06-06 NL NL7307867.A patent/NL160814C/xx not_active IP Right Cessation
- 1973-06-07 DD DD171393A patent/DD109211A5/xx unknown
- 1973-06-07 JP JP6435173A patent/JPS5715591B2/ja not_active Expired
- 1973-06-07 DD DD180810*A patent/DD115687A5/xx unknown
- 1973-06-07 LU LU67754A patent/LU67754A1/xx unknown
- 1973-06-07 CH CH1535876A patent/CH591511A5/xx not_active IP Right Cessation
- 1973-06-07 CH CH831273A patent/CH593929A5/xx not_active IP Right Cessation
- 1973-06-07 FR FR7320753A patent/FR2187344B1/fr not_active Expired
- 1973-06-07 YU YU01526/73A patent/YU36498B/xx unknown
- 1973-06-07 CS CS734136A patent/CS200166B2/cs unknown
- 1973-06-07 BE BE1005125A patent/BE800580A/xx not_active IP Right Cessation
- 1973-06-07 DE DE2329092A patent/DE2329092A1/de not_active Ceased
- 1973-06-07 AT AT504873A patent/AT340069B/de not_active IP Right Cessation
- 1973-06-07 CH CH1535976A patent/CH605887A5/xx not_active IP Right Cessation
1974
- 1974-03-11 NO NO740850A patent/NO142784C/no unknown
- 1974-09-26 ES ES430416A patent/ES430416A1/es not_active Expired
- 1974-09-26 ES ES430417A patent/ES430417A1/es not_active Expired
1975
- 1975-06-06 FR FR7517790A patent/FR2273814A1/fr active Granted
- 1975-06-25 PH PH17314A patent/PH13092A/en unknown
1976
- 1976-07-19 SE SE7608224A patent/SE418744B/xx unknown
- 1976-07-19 SE SE7608225A patent/SE7608225L/xx not_active Application Discontinuation
1977
- 1977-02-23 IL IL51525A patent/IL51525A0/xx unknown
1978
- 1978-12-14 NL NL7812163A patent/NL7812163A/xx not_active Application Discontinuation
1981
- 1981-06-10 JP JP8940881A patent/JPS5731692A/ja active Pending

Also Published As

Publication number	Publication date
SE7608225L (sv)	1976-07-19
FR2187344B1 (xx)	1977-10-28
HU170200B (xx)	1977-04-28
PH13092A (en)	1979-11-27
NL7307867A (xx)	1973-12-11
IE38058L (en)	1973-12-07
IL42385A (en)	1979-10-31
ATA504873A (de)	1977-03-15
SE415883B (sv)	1980-11-10
ES430417A1 (es)	1977-03-01
AU5643173A (en)	1974-12-05
IL51525A0 (en)	1977-04-29
FR2273814A1 (fr)	1976-01-02
CH593929A5 (xx)	1977-12-30
SE418744B (sv)	1981-06-22
AR207434A1 (es)	1976-10-08
JPS4954350A (xx)	1974-05-27
DD109211A5 (xx)	1974-10-20
LU67754A1 (xx)	1973-12-14
CH605887A5 (xx)	1978-10-13
YU152673A (en)	1982-02-25
ZA733763B (en)	1974-04-24
DE2329092A1 (de)	1974-01-03
HU170491B (xx)	1977-06-28
NO146538B (no)	1982-07-12
NO142784C (no)	1980-10-15
SE7608224L (sv)	1976-07-19
HU170487B (xx)	1977-06-28
NL160814B (nl)	1979-07-16
IL42385A0 (en)	1973-07-30
FI58327C (fi)	1981-01-12
FR2273814B1 (xx)	1977-07-08
NL160814C (nl)	1979-12-17
NO146538C (no)	1982-10-20
AT340069B (de)	1977-11-25
CA985280A (en)	1976-03-09
JPS5715591B2 (xx)	1982-03-31
ES415611A1 (es)	1976-07-16
GB1439512A (en)	1976-06-16
PH14204A (en)	1981-04-01
NL7812163A (nl)	1979-04-27
IN138966B (xx)	1976-04-17
YU36498B (en)	1984-02-29
BE800580A (fr)	1973-12-07
DD115687A5 (xx)	1975-10-12
NO142784B (no)	1980-07-07
JPS5731692A (en)	1982-02-20
IE38058B1 (en)	1977-12-21
GB1439511A (en)	1976-06-16
NO740850L (no)	1973-12-10
CH591511A5 (xx)	1977-09-30
FR2187344A1 (xx)	1974-01-18
ES430416A1 (es)	1976-10-16
FI58327B (fi)	1980-09-30

Publication	Publication Date	Title
EP0055208B1 (de)	1985-03-13	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0299914B1 (de)	1993-04-07	9-Halogen-(Z)-prostaglandinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA1091226A (en)	1980-12-09	Prostane derivatives and process for their manufacture
EP0030377A1 (de)	1981-06-17	9-Chlor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel
JPH0443906B2 (xx)	1992-07-20
DE2517771A1 (de)	1976-10-28	Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
DE2753244A1 (de)	1979-06-07	Neue prostacyclinderivate und verfahren zu ihrer herstellung
US4004020A (en)	1977-01-18	Novel prostanoic acid derivatives and process for the preparation thereof
EP1082299B1 (en)	2004-06-30	C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
US4088775A (en)	1978-05-09	15-Ethylenedioxy-prostanoic acid derivatives and esters thereof and intermediates thereof
IE47549B1 (en)	1984-04-18	Acetyleneprostaglandins and process for their production
US4626597A (en)	1986-12-02	16-fluoro-16,17-didehydro prostanoids and process for their preparation
CS200166B2 (en)	1980-08-29	Method of producing n-substituted prostaglandincarboxamides
EP0069049B1 (de)	1986-05-21	Delta 8,9-Prostaglandinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IE43465B1 (en)	1981-03-11	11-oxo-prostaglandin derivatives and process for their manufacture
WO1999012899A1 (en)	1999-03-18	A process for making prostaglandin f analogs
DE2907118A1 (de)	1980-09-04	Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3104044A1 (de)	1982-08-26	Neue prostacyclin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4094899A (en)	1978-06-13	Oxaprostaglandins
US4113766A (en)	1978-09-12	Oxaprostaglandins
WO1986000895A1 (en)	1986-02-13	New carbacyclines, preparation thereof and drug containing them
US4246280A (en)	1981-01-20	20-Alkoxy-16-alkyl-prostadienoic acid derivatives
DE3146278C2 (de)	1984-10-31	cis-Bicyclo[3.3.0]octanderivate, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser Verbindungen
US3989736A (en)	1976-11-02	Prostaglandin 5-indanyl esters
WO1987003283A1 (en)	1987-06-04	New carbacyclines, process for their production and their use as medicaments